Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.

Petrelintide/CT-388, amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate Phase 2 trials with petrelintide/CT-388 in the first half of 2026. Dapiglutide ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...